In this mini-review a number of novel outcomes, originating from studies in the field of PAMAM dendrimers, are presented and discussed. Owing to the multi-disciplinary nature of dendrimer chemistry it seems important to focus on the relevant topical research of PAMAM dendrimers, including their function, toxicity, surface modifications, and also possible new applications of these spherical polymers. We also consider the possibilities of specific functionalisation of PAMAM dendrimers -both novel ideas and those that have already been reported; as well as their cell-mediated effects (toxic and non-toxic). Then the reactivity of dendrimers' terminal groups, and their anticipated protective role against modifications of biomacromolecules, are discussed with regard to future developments in biomedical research. 
Introduction
In synthetic organic chemistry the creation and design of dendritic compounds is a relatively new field. The first successful attempt to form dendritic structures by organic synthesis was carried out by Vögtle and co-workers in 1978 [1] . However, after this first report several years passed before the field was moved forward by researchers from Tomalia's group at Dow Chemicals.
They developed a new class of amide containing cascade polymers, which brought these hitherto quite small molecular motifs into well-defined macromolecular dendritic structures.
Currently, there are a few commercially available types of dendrimers, which differ between each other by their mode of synthesis, structural behaviour, base core and terminal groups. Among these, five classes have been distinguished: (a) MAP-dendrimers (Multiple Antigen Peptide) -polymers based upon a polylysine skeleton; (b) PPI-dendrimers (Poly(PropyleneImine) dendrimers) -poly-alkylamines having primary amines as end-groups, with the interior consisting of numerous tertiary tris-propylene amines, sometimes also denoted as "DAB-dendrimers", where DAB refers to the core structure, which is usually based on DiAminoButane; (c) PEI-dendrimers -a less common sub-class of PPI dendrimers based on Poly(EthyleneImine) dendritic branches and ethane-1,2-diamine or propane-1,3-diamine core; (d) PAMAM-dendrimers, where 'PAMAM' stands for Poly(AMido)AMine and refers to one of the original dendrimer types built by polyamide branches with tertiary amines as focal points, and (e) Fréchet-type dendrimers -a more recent type of dendrimers based on a poly(benzyl ether) hyperbranched skeleton [2] . The most widely used in biomedical fields are PAMAM, as well as PPI dendrimers [3] .
Poly(amido)amine (PAMAM) dendrimers with an ellipsoidal or spheroidal shape are one of the most extensively studied Starburst™ macromolecules. The term "Starburst dendrimers" is applied as a trademark name for the sub-class of PAMAM dendrimers. The name refers to the star-like pattern observed when looking at the two-dimensional structures of the highgenerations of this type of dendrimers. These polymers are usually known under the abbreviation of 'PAMAM (Starburst)' of just 'Starburst' [4] . Due to a specific synthesis, PAMAM dendrimers have some interesting properties (see below), which distinguishes them from classical linear polymers [5] . Since the pioneering works of Tomalia and Newkome on poly(amido)amine (PAMAM) dendrimer synthesis in the early 1980s [6, 7] , several research groups have contributed considerably to our knowledge of both synthetic methodologies and specific applications in this field. There is continued effort to improve efficiency and to lessen the cost of synthesis of these spherical polymeric macromolecules. In the course of earlier and recent investigations the specific physical and chemical properties of PAMAM dendrimers have also been examined and revealed. Hence, although numerous aspects of dendrimer biology still remain unknown or elusive, the potential applications of dendrimers are relatively forthcoming. The high level of control over PAMAM dendrimers architecture, their size, shape, branching length, density, and their surface functionality, make these compounds ideal agents in biomedical applications. The explosion of interest in dendrimers as (a) active therapeutic agents, (b) vectors for targeted delivery of drugs, peptides or oligonucleotides, and (c) permeable enhancers capable of promoting oral and transdermal drug delivery, makes it timely to thoroughly review the current knowledge regarding dendrimers' pharmacology, including their toxicity. The toxicity of PAMAM dendrimers is generally considered to be species-, dose/concentration-, exposure duration-, and generation (size)-dependent, and is thought to be influenced by the nature of the terminal groups (full-generation cationic or half-generation anionic) [8] . Large dendrimers (above 5 th generation) have a densely packed surface structure and a relatively free interior space. Therefore, the short-term cytotoxicity of sufficiently large dendrimers is predominantly determined by the nature of their surface functionalities [9] . Although there are several examples of considerable cytotoxicity for large dendrimers (described in detail below), their surface functionality can however be modified so that they become water-soluble and neutral. Such surfacemodified molecules have been successfully explored as biomedical scaffolds (see below).
Although there is widespread concern as to the safety of nano-sized particles, the data regarding the chemistry of biomedical polymers and polymer therapeutics shows that judicious progress in PAMAM dendrimer chemistry for each specific application will likely ensure further development of important and safer materials for biomedical and pharmaceutical use. In this context, we review the current trends in using PAMAM dendrimers, emerging from the outcomes of both in vitro and in vivo studies, with particular emphasis on the role of terminally modified PAMAM dendrimers, as potentially efficient agents in the fields of chemistry, biology and medicine.
PAMAM dendrimers -a new but well recognized class of pharmaceutical agents
The number of research investigations into synthetic methodology, as well as physical and chemical properties of PAMAM dendrimers, is increasing exponentially with the ever growing interest in this field. Novel potential applications for amine-terminated dendrimers are now forthcoming. PAMAM dendrimers are composed of an initiator ethane-1,2-diamine core with layers of radially repeating units attached to the core, and an outer surface composed of terminal functional units. Each branched layer of these macromolecule makes up a single generation, which defines the size and characteristics of a given dendrimer. Full-generations of PAMAM dendrimers terminate with amine groups, while half-generation dendrimers terminate with carboxylic acid groups (Figure 1) . Thus, the interior and/or exterior of a dendrimer host can be cationic, anionic or non-ionic, depending on their termini, interior functionalities and pH. The chemical nature of the outer functional groups provides many of the unique properties of dendrimers, such as their peculiar solubility and reactivity. These functional surface groups are responsible for high reactivity, which means that dendrimers can be modified or conjugated with a variety of interesting guest molecules. Thus, the highly branched, multivalent and multifunctional surface of PAMAM dendrimers allows for manipulation of their surface chemistry, and their relatively solventfilled interior core renders them useful for several pharmaceutical applications in many fields. Among these applications is the encapsulation and solubilisation of drugs, using dendrimers as carriers for the delivery of drugs via the gastrointestinal tract, the delivery of DNA or oligonucleotides, and the development of targeted delivery systems [10] . However, despite extensive interest in the medical applications of PAMAM dendrimers, there is conflicting evidence regarding their biological safety, and properties associated with their ionic nature [11] . In 1986 the European Society for Biomaterials defined the need to consider the suitability of a material both in respect of its potential detrimental effect(s) in the body (toxicity), and in respect of any potential detrimental or beneficial effect(s) from the physiological environment on the performance of the material [12] . Therefore, there is a need to thoroughly assess and characterize the toxicity of PAMAM dendrimers prior to their use in diverse biomedical applications.
PAMAM dendrimers in in vitro studies

In vitro effects of PAMAM dendrimers on cellular membranes
In many studies, researchers have examined and defined dendrimers' cytotoxicity under in vitro conditions. They have employed different cell lines, a variety of incubation times (from hours to days) and various assay methods [11, [13] [14] [15] [16] [17] [18] [19] [20] . Hence, such the variability of cell lines used, and other biological material, as well as heterogeneity of experimental conditions employed, make it difficult to directly compare the experiments conducted in different laboratories. Nevertheless, some general trends seem to be clear. As has been widely documented, [22] . They noted that whilst generation 7 PAMAM dendrimers (10-100 nM) caused the formation of holes, dendrimers of generation 5 were only able to expand the holes of existing defects. Using a BCA protein assay, the researchers revealed that PAMAM G5 dendrimers were neither cytotoxic nor lytic at concentrations up to 500 nM. Interestingly, two hours following removal of the dendrimer, membrane integrity was re-established [22] . With the increasing interest in possible uses of dendrimers for oral delivery, their toxicity has also been examined using a variety of gastrointestinal tract models. The in vitro study of Duncan and Izzo, which was aimed at monitoring the rate of glucose active transport across rat everted gut sac upon exposure to PAMAMs, demonstrated that tissues exposed to anionic dendrimers (G2.5 and 3.5, up to 100 μg/ml, 2 h) had a greater ability to transport glucose than PAMAM dendrimers of the full-generation G4 [23] . PAMAM G4 exhibited toxicity in a concentration-dependent fashion, and resulted in barrier breakdown at 100 μg/ml (c.a. 7 µM). Using Caco-2 cells as an in vitro model and a MTT assay as a measure of cell viability, Jevprassesphant et al. systematically studied the cytotoxicity of various cationic PAMAM dendrimers (generations 2 to 4, incubation times of up to 3 h, concentrations up to 100 μM) [10, 19] . Whereas cationic PAMAMs showed concentration-and generation-dependent cytotoxicity, anionic generations 2.5 and 3.5 remained non-toxic.
Duncan et al. used Caco-2 cells to monitor the effects of PAMAM dendrimers on the integrity of monolayers, as assessed by measuring either the rate of transport of [ 14 C]mannitol, or the ongoing changes in transepithelial resistance (TEER). Their findings revealed that anionic PAMAM dendrimers had no effect on TEER, while cationic PAMAMs reduced TEER markedly. Nevertheless, transepithelial resistance recovered over time once the dendrimers were removed [23] .
Red blood cell (RBC) lysis is a simple and widely used method to study polymer-membrane interactions as it gives an easily accomplished quantitative measure of cell lysis based on haemoglobin (Hb) release from erythrocytes [23] . The data obtained in several such studies may also provide a qualitative indication of the potential damage to RBCs upon treatment with fullgeneration cationic dendrimers. Subtle differences in haemolytic behaviour have been seen depending on the chemical structure of the dendrimer under study. Despite the fact that rather a huge array of data has been collected, they appear a little confusing at first sight, as far as various concentration ranges and PAMAM generations have been tested. In general, it was noted that cationic PAMAMs (except generation 1) -when used at concentrations above 1 mg/mldemonstrated generation-dependent haemolysis following 1 h incubations. Moreover, even at the lower, non-haemolytic concentration of 10 μg/ml, cationic PAMAM dendrimers caused substantial changes in RBC morphology [20, 23] . RBCs typically adopted a round appearance after incubation with cationic dendrimers, and cells were often seen to aggregate. Exposure to higher dendrimer concentrations (1 mg/ml) exaggerated this "clumping" behaviour, and membrane damage was even more evident. Nevertheless, RBCs exposed to anionic PAMAM dendrimers of generations 3.5 to 9.5 showed no evident morphological changes up to a concentrations of 2 mg/ml [24] . The study of Domanski et al. revealed that PAMAM dendrimers of generations 2, 3 and 4 caused concentration-and generationdependent haemolysis, which was preceded by shape changes of erythrocytes, occurring even at very low concentrations [25] . The presence of 1 nM PAMAM G4 (14 ng/ml) in cell suspension induced echinocytic transformation. Cells displayed a characteristic irregular contour due to folding of the cell periphery. At higher dendrimer concentrations (10 nM, 140 ng/ml), elongated and spindle-shaped cell forms were observed. Furthermore, drephanocyte-like forms in 100 nM (1.4 µg/ml) dendrimer solution were recorded. Erythrocytes underwent similar transitions upon the addition of PAMAM G2 and G3 dendrimers. The authors suggest that cationic PAMAM dendrimers are able to come close to the red blood cell surface as a result of electrostatic attraction. Thus, the formation of erythrocyte aggregates may equally be the consequence of cell cross-linking by dendrimers. IC 50 values (defined as the concentration for which 50% release of haemoglobin was observed) for PAMAM G2, G3 and G4 were 735, 77 and 28 μM, respectively [25] . On the other hand, another in vitro study on the effect of PAMAM G4 on RBC lysis showed no evident haemolysis up to the high concentration of 50 µM (over 0.7 mg/ml, up to 24 h) [26] .
In vitro effects of PAMAM dendrimers on mitochondria
PAMAM dendrimers have been used for a variety of biologically relevant applications. Hence, their possible impact on sub-cellular structures and organelles has occasionally been anticipated. One of the first, and very intriguing, ideas was to test the biological effects of PAMAM dendrimers on cell mitochondria. Until now there have been no studies describing the interaction between dendrimers and mitochondria, which are considered crucial intracellular targets for these polymers. Our preliminary observations originating from in vitro experiments, briefly reported below, may shed new light on dendrimer activity and properties in the cell interior. The main conclusion of our initial report is that the tested PAMAM dendrimer G3.5 slightly affects selected parameters of rat liver mitochondria. After longer preincubation (up to half an hour) at concentrations of up to 50 μM the agent depolarised mitochondrial membrane and suppressed Ca 2+ transport to mitochondria. The promising aspect of this study was the fact that the tested dendrimer acted as a protective compound against depolarisation, induced by overload with Ca 2+ ions. Although the mechanism by which G3.5 may induce reduced mitochondrial membrane potential, and decreased internal concentration of Ca 2+ , remains to be explored in detail, we suggest that anionic PAMAM dendrimers can affect the membrane(s) of mitochondria and change their functional parameters [27] .
When comparing the action of anionic (PAMAM G3.5) and cationic PAMAM dendrimers of various generations (G2 and G4) on mitochondrial membrane(s) under in vitro conditions, it appeared that all tested dendrimers fluidised mitochondrial membranes, and led to mitochondrial depolarisation, along with intramitochondrial calcium redistribution and impaired oxidative phosphorylation. Interestingly, cationic and anionic PAMAM dendrimers exhibited distinct and opposing in vitro effects on isolated rat liver mitochondria. While no measurable toxicity up to concentration of 30 µM was recorded for PAMAM G3.5, the polycationic PAMAMs (G2 and G4) showed a marked toxicity towards the selected parameters of mitochondrial respiratory capacity (including RCI -an indicator of mitochondrial membrane functional integrity; OPR -oxidative phosphorylation rate; and ADP:O -the coefficient of oxidative phosphorylation) at concentrations slightly above 1 µM. As shown in Figure 2 , the IC 50 values estimated for PAMAM G4 were 3-7-fold lower compared to those of PAMAM G2, which suggests that the mitochondria were much more sensitive to PAMAMs of higher full-generation. Interestingly, RCI appeared the most affected mitochondrial respiration parameter. On the contrary, half-generation PAMAM G3.5 negligibly affected mitochondrial respiration and phosphorylation when used at concentrations that were toxic for either PAMAM G2 or G4. This data revealed that despite the detrimental effects of the tested compounds on components of mitochondrial membranes, crucial in cell respiration, their impact on general ATP production is impassive, except for G4 at 2 μM. However, we did not notice the impact of PAMAMs on basal respiration, which remained unchanged for all used dendrimers.
In search for a plausible interpretation and significance of these findings, we feel it important to point out the existing differences in structure and characteristics of the plasma and mitochondrial membranes. Importantly, the whole mitochondrial 'respiratory machinery' is isolated from the cellular surrounding by two distinct 50 (the concentration for which 50% inhibition occurs) values for PAMAM G4 (dark grey) and G2 (light grey), iterated from the relationships between dendrimer G2 or G4 concentration (x), and a reduction in mitochondrial oxidation/phosphorylation in the presence of glutamate/malate (y). The numerical values of mean ± SEM placed above the bars represent the inhibition by PAMAM G3.5, calculated for the IC 50 concentrations estimated for G2 or G4. The estimated IC 50 values for PAMAM G4 were significantly lower than for G2 (P< 0.002 by Mann-Whitney U test).
membranes, with quite a unique membrane lipid composition and membrane protein characteristics. In contrast to plasma membranes (typically made up of two layers of phospholipids with embedded proteins), two mitochondrial membranes serve to separate two compartments: the intermembrane space and the inner compartment, filled with the mitochondrial matrix. Noticeably higher proportions of membrane proteins (c.a. 80%), as well as the occurrence and/or abundance of peculiar membrane lipids (like cardiolipin, accounting for over 10% of the lipid component in bilayers), remain relevant to functional, as well as evolutionary autonomy of these organelles [28] . The differentiated structure and composition of plasma and mitochondrial membranes are likely to result in the apparently diversified effects of PAMAM dendrimers towards these two cellular targets, and such an interesting divergence certainly requires further studies.
Altogether, these findings clearly demonstrate that full-generation PAMAM dendrimers not only affect the function of mitochondrial membrane(s), but apparently also impact the oxidative phosphorylation and respiratory activity of rat liver mitochondria. What emerges from this study is that G4 appears more toxic towards mitochondria in comparison to G2, while on the other hand G3.5 shows little or no detectable toxicity. Overall, these preliminary data indicate that both cationic and anionic PAMAM dendrimers are able to alter mitochondrial function, and therefore any studies on interactions between dendrimers and mitochondria certainly deserve further attention.
PAMAM dendrimers in in vivo studies
There are numerous in vitro studies demonstrating the usefulness of dendrimers as a drug or gene delivery tool, but very few in vivo studies have been performed with PAMAM dendrimers. Nevertheless, the occasional experiments carried out using laboratory animals (mostly rodents) for testing the biological activity and tolerability of PAMAM dendrimers are very important, and may give us valuable insight into the pharmacological aspects of the chemistry of these compounds.
In studies with cationic PAMAM dendrimers, Roberts et al. administered compounds of generations 3, 5 and 7 to mice at doses of 2.6, 10 and 45 mg/kg, respectively. The dendrimers were given either as a single bolus, or repeated once a week for 10 weeks, with observation continued for either 7 days or 6 months, respectively. The animals were monitored for behavioural abnormalities for 2 h after injection, then observations were continued for 7 days or 6 months. Although no considerable behavioural changes or weight loss was reported over a 2 h period, at about 24 h after the administration of PAMAM generation 7 about 20% of animals died, but only in the 7-day branch of the experiment. Otherwise, all animals showed a normal growth pattern with no statistically significant differences in body weight between treated and control groups. Whether these surprising findings are accidental was not further verified, nor reasonably interpreted, by the authors. In the multiple dose study some degree of liver cell vacuolation was also observed [11] .
The other studies have shown that intraperitoneal dosing of G3, G4 and G5 dendrimers is not toxic when the agents were administered as a single or repeated bolus to male Swiss-Webster mice (e.g. did not induced behavioural abnormalities, increased mortality, altered body weight, and/or macroscopic or histopathologic tissue abnormalities). Likewise, exposure to PAMAM G3.5 dendrimers caused no adverse weight changes or signs of toxicity in C57 mice administered with a daily intraperitoneal dose of 95 mg/kg for 3 days. However, it should be emphasised that the short-term posttreatment observation in this study considerably limits its usefulness and allows no comparison to other relevant studies [8, 29] .
In our investigation, Wistar rats with induced streptozotocin diabetes have been treated with PAMAM G4 at a dose of 0.5 μmol/kg/day for a period of 2 months. Based on the results obtained we concluded that PAMAM G4 significantly reduced the survival of rats. The treated animals were 6.7 times more likely to die than control group. The mean survival time was 39 days for the PAMAM G4 administrated group and 65 days for the reference group. Despite the rather promising finding that PAMAM G4 treatment suppressed diabetes-associated complications (hyperglycaemia, AGEs, AOPP, plasma cholesterol, triglycerides etc.), the overall impact of this dendrimer on animal mortality was negative, indicating that such a beneficial effect cannot compromise PAMAM's G4 toxicity [26] .
The outcomes of these in vivo studies support other reports on cell culture and haemolysis, which suggest that the toxicity is generation (dendrimer size)-dependent, and that cationic dendrimers are more cytotoxic than their anionic counterparts. Taken together, these findings, along with the promising possibility of conjugating PAMAM dendrimers with certain biologically relevant molecules, make the dendrimers of low generations rather promising agents for biomedical treatments, where their protective function could be used against diverse effects in a plethora of diseases e.g. cancer, diabetes or neurodegenerative disorders.
Effect of PAMAM dendrimers on mitochondria isolated form rats with experimental diabetesan in vivo evaluation
Hyperglycaemia has been indicated as one of the main causes of altered mitochondrial function in diabetic animals. General consensus points to the formation of glycation and oxidative stress products as the main mechanisms by which hyperglycaemia affects mitochondrial and cellular function in diabetes [30] .
Based on this knowledge, we proposed for the first time to use PAMAM dendrimer G4 as a useful agent in reducing the detrimental effects of diabetes in an animal model. With the purpose of understanding the physiological and pathological changes occurring in this complex disease, animal models for diabetes are important research tools since they allow tight control of experimental conditions, which is almost impossible to achieve in any prospective study carried out on human populations [31, 32] . Our first report [26] revealed that G4 poly(amido)amine dendrimers administered to rats with streptozotocindiabetes acted as scavengers for excess glucose, and greatly suppressed the accumulation of diabetesassociated products of protein glycation, glycoxidation or/ and oxidation. Hence, we further expected that improved glycaemic control, modulated in such a way, should also contribute to the normalized function and improved respiration capacity of heart and liver mitochondria in diabetes. However, although we confirmed that PAMAM G4 dendrimers in vivo alleviated several hallmarks of carbohydrate metabolism impairments in experimental diabetes in rats, despite these beneficial effects of G4 dendrimers on glycaemic control, these agents impaired the function of heart mitochondria, to even higher extent than diabetes itself ( Figure 3 ). This means that regardless of normalizing the hallmarks of diabetes severity, PAMAM G4 did not restore heart mitochondrial respiration capacities which are apparently reduced in diabetic animals. Such an observation may point to the toxic effect of poly(amido)amine dendrimers on heart mitochondria. Conversely, we revealed the opposing tendency of a slightly increased oxygen uptake and respiration index in liver mitochondria originating from the same animals receiving PAMAM G4, which encourages us to speculate that liver mitochondria -in contrast to liver tissue -may not be so sensitive to PAMAM G4 toxicity. To reasonably reconcile this apparent disparity, we need to remember that heart and liver mitochondria are evidently charged with different metabolic tasks. Heart cells and mitochondria are probably much more sensitive to the cytotoxic action of PAMAM, and the overall response toward dendrimer toxicity is simply the suppression of mitochondrial metabolism and phosphorylation. The liver, on the other hand, is the main "detoxication factory" in the body, designed to metabolise various toxic agents, and is thus, possibly much better suited to cope with the cytotoxic effects of dendrimers. Unchanged or even slightly elevated mitochondrial function in hepatocytes may thus reflect the vastly accelerated metabolic turnover in liver mitochondria in response to the toxic PAMAM G4. Interestingly, together with the essentially unchanged mitochondrial lipophilic antioxidants upon PAMAM treatment, these data support the argument that PAMAM G4 did not increase mitochondrial oxidative stress, which remains consistent with the PAMAMmediated increased respiration in the presence of ADP in hepatocytes [33] . The toxic effects of PAMAM on mitochondrial function most likely concern either the integrity of mitochondrial membrane(s), or impaired activity of the particular enzymes engaged in oxidative phosphorylation. The former seems less reasonable, as far as the activities of mitochondrial cytochrome C oxidase did not differ in animals treated with PAMAM G4 ( Figure 3C insert), which clearly indicates that PAMAM G4 did not cause considerable damage in the integrity of mitochondrial membrane(s), and the possible leakage of the enzyme from mitochondria [34] .
3.
Surface-modified PAMAM dendrimers mean more safe dendrimers -general impressions on reducing dendrimer's toxicity
The inherent toxicity associated with polycationic polymers, such as dendrimers, limits their clinical usefulness. It is thought that the cytotoxicity of cationic PAMAM dendrimers is the result of interactions between positively charged dendrimers and negatively charged molecules located on the cell surface [20] . Noteworthy, the modification of cationic dendrimers with other molecules is likely to decrease the positive charge on the dendrimer surface, and lead to a gradual decrease in cytotoxicity. Hence, the biological profile of dendrimerbased delivery systems is thus likely to differ between dendrimers with surface modifications and those that are unmodified [10] . Indeed this has been demonstrated for DNA/PAMAM dendrimer complexes [35] and oligonucleotide-dendrimer complexes [36] .
Among the numerous options yet to be explored in order to overcome this substantial limitation, the modification of dendrimers via the attachment of other molecules (e.g. PEG, polyethylene glycol) to dendrimers' surface groups seems prominent [37] . PEG has become an agent of particular interest in the design of dendrimer systems for pharmaceutical applications because of its high water solubility, biocompatibility and ability to modify the bio-distribution of carriers [38] . Kim et al. reported numerous examples of attaching PEG to dendrimers through the formation of different types of bonds, creating hybrids to various geometries, among which the application for drug delivery has been the most prevalent one [39] . By conjugating the PEG monoethyl ether to the periphery of PAMAM G4 dendrimer, Bhadra et al. generated a desirable dendritic architecture for delivery of the anticancer agent 5-fluorouracil, which imparted two positive features to the nanometric drug carrier. First, the drug loading capacity to the dendrimer was enhanced significantly; and second, the haemolytic toxicity of PEGylated dendrimers was considerably minimized compared to non-PEGylated systems [40] .
Because of the toxicity of polycationic PAMAM dendrimers, various strategies have been applied to conceal the terminal amino groups. Among them, the partial acetylation of PAMAM surfaces, where a fraction of the toxic amino groups was left uncovered to achieve desirable properties, affected the water solubility and reduced the hydrodynamic volume [41, 42] . Partial conversion of cationic PAMAM dendrimers into lauroyl end groups increased membrane permeability and reduced cytotoxicity [10, 19] . Noteworthy however, this modification may -on the other hand -also increase hydrophobicity, and promote aggregation in water through attached aliphatic chains. Still other examples, such as the modification by small alkyl alcohol groups, also point to reduced cytotoxicity along with maintained water solubility [43, 44] . Overall, PAMAM surface modification by relatively small functional groups requires complex tuning of the stoichiometry for each appended functional moiety to achieve both the desired physicochemical and pharmacological properties.
A marked decrease in the cytotoxicity of cationic PAMAM dendrimers was noted when cells were exposed to lauroyl-PAMAM dendrimers. As deduced from the determined IC 50 values, the cytotoxicity of conjugates of PAMAM G3 and G4 dendrimers with six attached lipid chains was more than 7-fold decreased compared to the unmodified dendrimers [10, 44] .
Acetylation of the reactive end groups of PAMAM dendrimers has been a route to specifically functionalize the primary surface amines. When dendrimers are acetylated, they become more water-soluble, and this quality is vital for biomedical applications that require solubility in aqueous solutions [42, 44, 45] . However, no systematic study of the chemistry involved in acetylation of PAMAMs has been performed. The first study related to acetylation of PAMAM G5 was conducted by Majoros et al., who designed their protocol to investigate the Figure 3 . Effect of PAMAM G4 administered to streptozotocindiabetic rats on oxidation and phosphorylation in heart and liver mitochondria in the presence of glutamate/malate. Median and lower-upper quartile ranges for mitochondria isolated from hearts (squares) and livers (circles) of control, healthy, non-treated rats, and streptozotocindiabetic rats, untreated or treated with PAMAM G4, are presented for: (A) RCI (S 3 *S 4 -1 ), respiration control index; (B) ADP:O, coefficient of oxidative phosphorylation; and (C) OPR, oxidative phosphorylation rate. Insert: Effect of dendrimer administered to diabetic rats on the activity of cytochrome c oxidase (COX) in hearts (squares) and livers (circles) of streptozotocin-diabetic rats, untreated (light grey), or treated with PAMAM G4 (dark grey). Significant differences were noted between non-diabetic and diabetic rats for all parameters in heart mitochondria, and for ADP:O and OPR in liver mitochondria (P<0.0001); OPR in heart mitochondria was reduced upon PAMAM G4 administration (P<0.05).
nature of the acetylation reaction used, and to provide an analysis of well-defined dendrimer conjugates for use in the biomedical field. Based on data obtained using several techniques, including potentiometric titration, GPC (gel permeation chromatography), 1 H NMR and 13 C NMR, the authors concluded that the acetylated dendrimers unexpectedly exhibit smaller molecular size despite their increasing molecular weight. Moreover, they represent a more compact structure than the nonacetylated analogues. Nevertheless, the converting of all primary amines to acetyl derivatives considerably alters the structure of the dendrimer. The re-location and/or disappearance of NMR characteristic spectral peaks, as well as the appearance of a few new peaks, allowed the authors to conclude that the modification process of PAMAM G5 may be considered as a controlled, stoichiometric reaction, where the ratio of the primary amine to the acetic anhydride is 1:1. These data show that the stoichiometric nature of the acetylation reaction, with knowledge of the exact number of primary amine surface groups, ensures a well-defined chemical structure for further dendrimer conjugates [43] .
In the study of Kolhathar et al. two different generations of PAMAM dendrimers, namely G2 and G4, were acetylated, and the effect of surface modifications on cytotoxicity, permeability and uptake was investigated using Caco-2 epithelial cells [46] . In their earlier report these authors showed that cationic PAMAM dendrimers may permeate across Caco-2 cells to a higher extent than their neutral or anionic counterparts [47] . Consequently, as their next step they used acetylated PAMAM dendrimers in order to limit PAMAMs cytotoxicity towards the tested cell line. Other factors that prompted the use of acetyl groups for surface functionalisation were as follows: (1) an increasing interest in surface modified dendrimers for drug delivery; (2) ease of controlling the degree of acetylation by controlling stoichiometry; (3) mild reaction conditions required for acetylation and (4) increased solubility of acetylated dendrimers. An evaluation of the effect of acetylated dendrimer concentration, and the relative degree of surface amine group acetylation on cell viability, revealed that cell incubation even with partially acetylated PAMAM dendrimers resulted in a much improved (greater than 90%) cell viability. Although the enhanced permeability of surface acetylated G4 analogues across Caco-2 cell monolayers has already been observed at a donor concentration of 10 µM, an additional increase in acetylation level did not further enhance permeability. A possible explanation for the increased permeability of acetylated G4 may be the ongoing reduction in non-specific binding. Thus, acetylated dendrimers feature reduced cytotoxicity while maintaining appreciable permeability. Taken together, the authors suggest that it is possible to tailormake surface-modified PAMAM dendrimers for specific biomedical applications [46, 47] . In addition Quintana et al. (2002) [42] reported that acetylation can be used to reduce the non-specific binding associated with amineterminated nanoparticles. A decrease in the number of positively charged surface groups may reduce the nonspecific interaction of acetylated PAMAM dendrimers with the negatively charged cell membrane. This, in turn, may result in a relatively higher concentration of free dendrimer at the apical side of the membrane, contributing to increased permeability through the paracellular route. These data are in agreement with studies by Wiwattanapattapee et al., who observed higher tissue uptake and lower serosal transfer rate for modified dendrimers, compared to non-modified ones [48] . Moreover, PAMAM dendrimers carry a large number of internal tertiary amine groups, which can potentially interact with negatively charged cell membranes, enhancing permeability.
Additional, indirect evidence for reduced toxicity of surface-modified PAMAM dendrimers comes from our own long-term observation on the survival rate of rats with experimental diabetes. In animals administered daily with PAMAM G4 (7-8 mg kg -1 , c.a. 5.8 μM in circulating blood) we revealed much improved glycaemic control markers of diabetes, although PAMAM-treated rats, with better metabolic control of chronic hyperglycaemia, were more likely to die. Thus, mortality was significantly reduced in animals with higher blood glucose [26] . Accordingly, we hypothesized that the pathophysiological but natural modification might be non-enzymatic modification(s) of dendrimeric free surface amino groups. Such a nonenzymatic covalent modification may also have possible implications for dendrimer pharmacokinetics. First, the clearance of the modified full-generation cationic PAMAMs would be retarded, retaining their longer bioavailability and making them more effective drug carriers, and hence more suitable for targeted delivery [49] . Second, PAMAMs with naturally modified amino groups by glucose would be expected to be less cytotoxic, as more advanced non-enzymatic modifications of their surface amino groups occur. Thus, higher blood glucose was demonstrated to be protective against polycationic PAMAM-mediated cytotoxicity and increased mortality under conditions of long-term chronic diabetes [26] .
Gene therapy is a new approach using PAMAM dendrimers to test, cure, or prevent interactive diseases like cancer, AIDS, Parkinson's or Alzheimer's disease, and arthritis [50] . To develop a transfection efficiency for PAMAM dendrimers, various ligands were conjugated on the PAMAM surface. A great deal of research has been done on introducing arginine into polymers such as PAMAM dendrimers to improve their transfection efficiency [14, 51] . The interesting studies of Nam et al. further confirmed that PAMAM dendrimers (G3 and G4) conjugated with arginine (PAMAM-R) or lysine (PAMAM-K) through an amide bound have been found to have better transfection properties compared to plain G3 and G4 [52, 53] . Moreover, the authors noticed that the attachment of arginine to PAMAM dendrimers through a biodegradable ester bond has at least two advantages. First, the introduced arginine affects polyplex formation and penetration into the cell membrane and nucleus. Second, the biodegradability of polymers affects the efficiency of intracellular disassembly for oligonucleotides and si-RNAs, and thus cell viability [52] . In their further report the authors used PAMAM-OH dendrimers that have the same structure as PAMAM-NH 2 , except the surface amine groups of cationic dendrimers are exchanged for hydroxyl groups. PAMAM-OH is relatively non-toxic due to the absence of surface primary amines, but it hardly forms polyplexes with DNA because of the low pK a value of the interior tertiary amines. To cope with this, they constructed biodegradable lysine (K)-and arginine (A)-conjugated PAMAM dendrimers having ester bonds between the surface hydroxyl groups of PAMAM-OH and the carboxylate groups of lysine and arginine (referred to as e-PAM-K and e-PAM-A, respectively). When the cytotoxicity of these modified PAMAM dendrimers was evaluated in HepG2 cells, smooth muscle cells (SMCs) and HUVECs (human umbillical vein endothelial cells) by MTT assay using PEI, PAM-R and PAM-K as control agents, it appeared that both e-PAM-R and e-PAM-K displayed the superior characteristics with respect to cell viability. They were almost non-toxic to HepG2 cells and toxic only in about 20% to SMCs or HUVECs when employed at 100 μg/ml. These newly synthesized biodegradable e-PAM-R and e-PAM-K dendrimers, which have a degradable ester bond in the arginine-and lysine-grafted PAMAM dendrimers, show the capability for reducing overall toxicity through blocking the accumulation of more toxic cationic polymers. Therefore, it is expected that PAMAM-OH dendrimers (specially those surfacemodified with arginine) will have excellent potential to be a safe gene delivery carrier possessing biodegradability, low cytotoxicity, and high transfection efficiency [53] . In a study performed by Pisal et al., the permeability across Caco-2 cell monolayers, and cytotoxicity of PAMAM G4 dendrimers conjugated with arginine and ornithine, was investigated [54] . The obtained data show that the surface modified dendrimers are transported across epithelial monolayers significantly faster than their unmodified counterparts [54] . Nevertheless, the mechanism by which the polyamines improve the permeation of dendrimers remains to be explored. Otherwise, toxicity tests revealed that PAMAM-arginine dendrimers have been found to be more toxic than ornithine-PAMAMs and crude PAMAMs. Whether it is reasonable to attribute the toxicity of PAMAM-arginine to elevated permeability remains to be established.
Taken together, the results above show that PAMAM dendrimers may be easily modified at their surfaces in the process of acetylation, acylation or glycation; and these modifications are likely to make PAMAM dendrimers less cytotoxic and much more useful for specific biomedical applications, e.g. oral drug or gene delivery. The nature and density of charged groups are another factor that may determine dendrimer's cytotoxicity. Cationic charges at the surface are usually cytotoxic, but it generally also depends on the chemistry of specific groups, as in the case of primary amines [55] . Once the cationic polymers form complexes, these complexes usually show lesser cytotoxicity than cationic free polymers. However, because any interactions with cellular components may cause damage to cells, the development of non-toxic cationic polymers is undoubtedly very important [52] .
PAMAM dendrimers -the unknown face
The defined structure of cationic PAMAM dendrimers and their large number of surface amino groups has led to interest in dendrimers as substrates for the attachment of antibodies, contrast agents and radionuclides for applications in a number of different areas of biology and medicine [4, [56] [57] [58] [59] [60] . As their surface is covered with primary amino groups, dendrimers are able to interact, on an electrostatic charge basis, with biologically relevant polyanionic macromolecules, such as proteins or nucleic acids; a feature that has been progressively developed and exhaustively studied [56, 61, 62] . On the other hand, due to the presence of numerous free primary amino groups on their surface, poly(amido)amine dendrimers are strongly nucleophilic molecules, and hence they appear to be potential candidates for the prevention of naturally occurring biomacromolecules against some non-enzymatic modifications, including carbonylation, acetylation, acylation and/or glycosylation. As such they may represent an important group of pharmaceuticals in targeting the excessive post-synthetic modifications of proteins under various clinical conditions. Such a tentative role of PAMAMs, as potential targets for nonenzymatically-driven modifications of biomolecules, has not been greatly appreciated thus far. The ability of these dendritic polymers to bind large numbers of ligands to their end groups might lead to novel applications as sequestering agents for metabolic "waste products" under states of imbalance between antioxidant defence and free radical production, like in diabetes, uraemia, cancer or aging.
PAMAM dendrimers in a "friendly embrace with sugar"
Hyperglycaemia causes increased protein glycation (and further glycoxidation) and the formation of both early and advanced glycation (end) procucts (AGEs), which are the major hallmarks of late complications in diabetes. The glycation process represents a common post-translational, non-enzymatic modification of biomacromolecules, mainly proteins, occurring under peculiar pathological conditions, such as those encountered during the course of diabetes or ageing.
In general, the short-lived molecules, such as proteins in plasma and blood, are expected to participate in the formation of early glycation products, while long-lived molecules, like collagens, lens crystalline, myelin and DNA, are expected to be altered as they irreversibly accumulate AGEs. The formation and accumulation of AGEs in various tissues has been shown to extend rapidly in some chronic diseases [63] . In living organisms proteins may be susceptible to modification by glucose or other reducing sugars through the non-enzymatic attachment of glucose to free amino groups. The initial step of this process is a simple condensation, largely reversible and proportional to both glucose concentration and time. At later stages the formed Schiff's base undergoes the so called Amadori rearrangement to form more stable early glycation ketoimine products; following subsequent degradation and cross-linking -the irreversible compounds are referred to as AGEs [64] . The accumulation of AGEs in the body leads to structural and functional modifications of tissue proteins, and there is emerging evidence that advanced protein glycation is implicated in the aging process, as well as the pathogenesis of the complications of diabetes [65] .
Based on this information, it appears that in general sugar moieties are able to participate in specific interactions with biomacromolecules, or function directly in biological events. Therefore, various sugar-modified dendrimers have been developed to evaluate the cluster effect of sugar moieties on the various biological functions of these polymers. For example, mannosemodified poly(L-lysine) dendrimers have been examined for their inhibitory behaviour with respect to the type 1 adhesion of fimbriated E. coli to equine red blood cells, when it emerged that a large number of mannose groups oriented on the periphery of the dendrimer could tremendously affect the adhesion [66] . It has also been revealed that carbohydrate coating on the dendrimeric system can reduce haemolytic toxicity by neutralizing cationic charges due to the presence of -NH 2 groups on the periphery of dendrimers [49, 67, 68] . In parallel, it has been revealed that glucose-modified PAMAM G4 dendrimers are characterized by a much reduced overall toxicity [26] . It has also appeared that modification with 'sugars' can help in targeting the system to active sites, with reduced immunogenicity, antigenicity and toxicity, by shielding the system from recognition by macrophages. Moreover, glycodendrimers offer the potential to serve as high-affinity ligands for clinically relevant sugar receptors [69] . Amongst various ligands, galactose has been found as suitable for liver targeting because of the asialo-glycoprotein receptors present on liver parenchymatous cells, which recognize galactose units on chemically conjugated drug carriers [70] . These reports suggest that PAMAM dendrimers can conjugate with sugars, which clearly indicates that their glycation is a possible manner of manipulation towards their reduced toxicity. Accordingly, we found quite a novel application for PAMAMs as agents inhibiting extensive non-enzymatic glycation of proteins in chronic experimental diabetes [26] . To the best of our knowledge, it is the first and only report published so far dealing with the pharmacological inhibition of protein glycation in experimental diabetes with the use of PAMAM dendrimers.
Novel applications behind the unknown face of PAMAM dendrimers -hope or disappointment ?
Occasionally, the hypothesis has been raised that PAMAM dendrimers with surface free primary amino groups may be able to compete with proteins for binding small nucleophilic molecules that are reactive towards primary amines, while not considerably affecting protein conformation. A recent preliminary report on the use of PAMAM G4 in animals with experimentally induced diabetes has demonstrated that the increased, non-enzymatic modification of proteins in experimental diabetes in animals may be vastly reduced in animals treated with PAMAM G4 [26] . It suggests that PAMAM dendrimers, rich in free primary amino groups, might indeed act as competing targets for non-enzymatically attached adducts; and more so considering the fact that such scavenging abilities may be accompanied by nonenzymatic modifications of dendrimer terminal amino groups. In this report we have shown that PAMAM G4 suppresses plasma hyperglycaemia in diabetic rats, and thus contributes to a reduced glycoxidation and post-synthetic non-enzymatic modification of biomacromolecules in long-term streptozotocin-diabetic rats (Figure 4) . Furthermore, the PAMAM-treated animals showed reduced concentrations of other parameters of metabolic control, including plasma cholesterol and triglycerides. Most likely, these beneficial and alleviating effects of dendrimer on diabetes-associated, metabolic impairments was not due to its cytoprotective effects on the pancreas, since we did not reveal any elevated generation of residual insulin in PAMAM-treated STZ (streptozotocin) -diabetic rats. Although this beneficial influence could not compromise PAMAM's G4 cytotoxicity, and its contribution to decreased animal survival [26] , along with their deteriorative effects on heart mitochondria (described above), the dendrimer clearly manifested its scavenging activity towards glucose under conditions of severe hyperglycaemia. Our data suggest that PAMAM G4, rich in free primary amino groups, may act as a competing target for nonenzymatically attached adducts, and shield natural protein amino groups against excessive modifications in poorly controlled diabetes. The obtained results provide some evidence to support this reasoning. First, PAMAM G4 considerably reduced the hallmarks of both early and advanced protein glycation/glycoxidation (glycated haemoglobin, advanced glycation end-products, AGEs) and protein oxidation (AOPP) in chronic experimental diabetes in animals, e.g. under conditions linked to augmented oxidative stress. Interestingly, due to the high content of negatively charged glycosaminoglycans in the extracellular matrix, polycationic dendrimers could accumulate in high concentrations in the vessel wall, where their impact on hampering non-enzymatic modifications of biomolecules might be underestimated [71] . Furthermore, the animals treated with PAMAM G4 regularly showed decreased concentrations of lipophilic antioxidants (coenzyme Q isoforms) in myocardium, liver and blood plasma. If we deny the preventive and protective role(s) of PAMAM G4 as anti-oxidation agents, we would expect elevated levels of these lipophilic antioxidants, commonly regarded as an adaptation to oxidative stress in diabetes [20, 33, 72, 73] . Coenzyme Q acts as an electron carrier from mitochondrial respiratory complexes I and II to complex III, and its fully reduced form (ubiquinol) is a potent antioxidant, preventing oxidative stress [74] . In rat mitochondria CoQ consists of two homologues, CoQ 9 and CoQ 10 . In Wistar nondiabetic rats CoQ 10 is known to comprise 10-16% of the total amount of mitochondrial CoQ, while in diabetic rats this ratio is between 8-12%. However, the content of CoQ forms has been reported to significantly increase in diabetic rats (up to 2.5 fold) [75, 76] . Treatment with PAMAM G4 suppressed the concentration of these antioxidants, typically elevated in diabetic rats, to levels relevant to non-diabetic animals [76] ; which may be regarded as indicative that PAMAM G4 had the ability to suppress oxidative stress in experimental diabetes rats. The increased antioxidant activity is likely triggered by persistent hyperglycaemic states as a response to oxidative stress in diabetes [33, 72, 73, 75, 76] , while it normalizes when high glucose, and the associated postsynthetic modifications of proteins, become ameliorated with the administration of PAMAM G4. It is of interest that a reduced form of cytochrome Q 9 occurred in the liver of diabetic rats treated with PAMAM G4, which encourages us to speculate that the dendrimers are likely to activate some defence mechanisms against oxidative stress in diabetes [77, 78] . Moreover, as mentioned above, PAMAM dendrimers with free surface amino groups Figure 4 . Effect of PAMAM G4 administered to streptozotocin-diabetic rats on plasma glucose, and the long-term hallmarks of glucose-mediated non-enzymatic modifications of plasma proteins. Data (mean ± SD) presented for non-diabetic, non-treated rats and streptozotocindiabetic rats, untreated or treated with PAMAM G4. Significant differences were revealed between non-diabetic, non-treated vs. STZ-diabetic, non-treated rats, and between diabetic, non-treated vs. diabetic, treated rats were: * P<0.0001, ** P<0.0003, # P<0.04 may easily undergo non-enzymatic glycosylation at these primary amino groups when incubated in vitro with high glucose concentrations (see below for a brief discussion). The precise mechanism(s) underlying such effects remains to be elucidated. The fact that PAMAM G4-mediated reductions in glycated haemoglobin, advanced glycation end-products, or advanced oxidation protein products, were far more pronounced than its influence on blood glucose levels [26] , discourage the notion that PAMAM G4 acts as a simple chemical competing between dendrimers and biomacromolecules for circulating free glucose.
Non-enzymatic glycosylation of PAMAM dendrimers under in vitro conditions -the first announcement
Non-enzymatic glycosylation (glycation), the reaction of glucose and other reducing sugars with another compounds carrying free amino groups (e.g. proteins, polypeptides polymers rich in amino groups, such as dendrimers), inevitably produces reversible Amadori products, and, when ocurring over a longer period, irreversible, advanced glycation end products. In diabetes these reactions are greatly accelerated, and are crucial in the pathogenesis of diabetic complications. Despite recent advances in the molecular pharmacology of anti-diabetic drugs, e.g. thiazolidinediones, metformin, or aldose reductase inhibitors, the inhibition of diabetesassociated glycoxidation still remains a major lifethreatening problem [79] . Therefore, some novel agents, including PAMAM dendrimers, have been examined as useful compounds in the inhibition of the detrimental effects of glucose overload. In this paper we have focused on PAMAM dendrimers as possible inhibitors of protein glycation, and other glucose-derived, detrimental phenomena. We found that the in vitro glycation of bovine albumin, a model protein with a strict relevance to human physiology and pathophysiology, may be competitively inhibited when using non-protein compounds carrying plenty of free amino groups. Based on our knowledge of PAMAM dendrimers we suggest that the higher the generation of PAMAM dendrimers, the higher degree of competition, and better activity towards scavenging glucose moieties. We hope that the glycation of dendrimers may effectively compete with modifications of other plausible targets for excessive glucose, like proteins or polypeptides. With the higher glycation levels of polyamine compounds comes the better prevention of other biological molecules against the detrimental effects of hyperglycaemia in diabetes. Considering our leading hypothesis that dendrimers and other polyamine compounds are able to compete with protein (BSA -bovine serum albumin) for binding ambient free glucose, we examined the chelating/scavenging activity of PAMAM G2 and G4 dendrimers , as well as a reference agent, a high molecular weight poly(L-lysine) (c.a. 70 kDa), for inhibition of the glycation of BSA in the course of prolonged incubation (3 days, 37°C, under unaerobic conditions), with very high glucose (30 mM, relevant to c.a. 500 mg/100 ml).
Our results suggest that dendrimers appear very effective in scavenging glucose and reducing BSA glycation ( Figure 5) . At first sight it may seem quite reasonable considering that dendrimers have a lot of vulnerable free surface amino groups per molecule (16 in PAMAM G2 and 64 in G4, compared to 60 ε amino groups in BSA, of which merely a portion is probably accessible for glucose attachment). Interestingly, however, another polyamine compound used in this experiment, poly(L-lysine), which has at least 500 free ε amino groups per molecule, did not demonstrate a significantly higher efficiency in reducing BSA glycation, compared to PAMAM G2 or G4 ( Figure 5 ). Quite likely the stereochemical properties of a given polyamine compound may stay behind the scenes and underlie the unexpectedly high yield of BSA protection by PAMAMs, compared to the reference compound, polylysine (MW 70 kDa and the number of free primary amino groups per molecule greater by a factor of 8 to 30). Furthermore, despite the fact that the structure of dendrimer G2 could make it more effective in glucose scavenging than PAMAM G4, due to a simple molecule geometry, the data did not reveal any differences in 'protective activity' between G2 and G4. It has been well documented that low generations of dendrimers have an open, flattened and asymmetric shape; but as the generation increases, the structure becomes more globular and densely configured [80] . The structure of dendrimers suggests that molecular density should be highest at the periphery of the dendrimers. However, this is not always true. Gorman et al. revealed that if dendrimer possess flexible branches, they can fold back towards their core. This can lead to a more uniform, or even reverse, density profile [81] . In the context of these data, our observations showed that regardless of the generation of dendrimer used, the scavenging activities of G2 and G4 are similar. Although, there was a high probability that amine primary groups at the surface of PAMAM G4 were folded inwards, and hence the dendrimers remained much less vulnerable for glucose attachment as a consequence of their structure, the level of PAMAM G4 glycation was apparently the same for PAMAM G2 and G4 ( Figure 5B ). With regards to the chemical nature of the 'scavenging ability' of dendrimers and polylysine, we explored in more detail the mechanism of simple chemical competition between the free amine groups of BSA, and the polyamine polymers and their modification by glucose. It appears that both PAMAM G2 and G4, as well as polylysine, have undergone a well-marked glycation ( Figure 5A ) (each amino group glycated per 3.2 groups, 2.3 groups or 5.9 amino groups available in PAMAM G4, G2 or polylysine, respectively) that was time-dependent, and proportional to the total number of primary amino groups per molecule ( Figure 5A, insert) .
What importance arises from this study for the potential use of PAMAM dendrimers as modulators of the non-enzymatic modifications of biomacromolecules under pathological conditions? First, as lower generations of PAMAM dendrimers do not yield to higher generations in their efficacy to inhibit protein glycation, and considering that they are certainly less cytotoxic, they should be preferentially used as pharmacological targets in such chemical prevention. Second, the dynamics of PAMAM glycation over time clearly suggests that permanent and often-reiterated low-dosing infusions might turn out to be a better way of administration than a single bolus of higher dose. Overall, the important message from this preliminary study is that it is certainly worthy to search for a compromise for using PAMAM dendrimers, despite their marked cytotoxicity. Finally, these speculations, derived from model in vitro studies, certainly need to be verified in animals with experimental pathology, before their further possible implementation in humans.
Future perspectives
Dendrimers offer several advantages over conventional polymers with respect to interactions with other molecules, including the fact that they are well-characterised molecules, allow the development of well-defined molecule/ polymer systems, and have the potential for high molecule payloads. Although the protective role of dendrimers against macromolecule modifications is in its infancy, these early observations offer an attractive feature. Due to the use of PAMAM dendrimers against detrimental proteins or other physiologically non-neutral molecules, the modification caused by toxicants or reactive oxygen species (ROS) remains a challenging area of research. Although this interest is likely to continue, one topic that requires further addressing is a full biological evaluation of these novel dendrimers' properties/activity. The outcomes of our preliminary studies point to novel strategies for using cationic PAMAM dendrimers, despite their potential cytotoxicity. Thus, some very interesting conclusions can be drawn from these studies. Poly(amido)amine (PAMAM) dendrimers G4 administered to rats with streptozotocindiabetes acted as scavengers of excessive glucose, and greatly suppressed the accumulation of diabetesassociated products of protein glycation, glycoxidation and/or oxidation; as well as some other markers of oxidative and carbonyl stress. Hence -by limiting the Differences were significant at P<0.004, μ G2 < μ BSA < μ G4 < μ G2 < μ polyLys . Insert: Time-dependent attachment of glucose (30 mM, 37°C) to PAMAM G4 (30 μM) (squares) and G2 (120 μM) (triangles) dendrimers (P<0.005). (B) Prevention of in vitro glycation of bovine serum albumin by polyamine compounds. Data (median and lowerupper quartile range) presented for BSA subjected to modification by glucose (30 mM, 3 days, 37°C) in control samples incubated without polyamine compound (light grey), or in the presence of PAMAM G4 or G2 (middle grey), or high-molecular weight poly(L-lysine) (dark grey). Significant differences were noted between control samples and BSA incubated in the presence of either polyamine compound, P< 0.0001.
progression of diabetic sequelae -PAMAM dendrimers might contribute to decreased severity of diabetes, and a suppressed mortality of diabetic animals. Also in vitro data on the inhibition of protein glycation using these polymers revealed that cationic PAMAMs are able to efficiently interact with glucose, and undergo relevant modification. Moreover, interactions between dendrimers and glucose were more profound than between BSA and glucose. Overall, these preliminary in vitro studies with PAMAM dendrimers as preventive agents towards non-enzymatic modifications of biomacromolecules, as well as the differentiated effects of various PAMAM generations on mitochondria, appear very promising with respect to a compromise between alleviated cytotoxicity and high biological activity.
With the growing number of potential glycation inhibitors, PAMAMs hold promise for use in the treatment of diabetic complications. However, further work is needed to define the relationship between dendrimers and other molecules for successful "dendrimer therapy". Nevertheless, this mini-review clearly illustrates the potential of PAMAM dendrimers, and substantiates high optimism for the future of polymers in this important field. The potent anti-glycation effect of PAMAM suggests their possible beneficial role in the prevention of glycationassociated malfunctions and disorders. Nevertheless, further studies on the in vivo impact of PAMAMs towards the inhibition of pathological modifications of biomacromolecules, like those occurring in diabetes, are certainly required and encouraged.
